ClinicalTrials.gg
Enrolling by invitationNCT06910072UPGRADE-TNBCUpdated Aug 18, 2026

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC)

A Phase 2/3 interventional study of paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab in Triple-Negative Breast Cancer (TNBC) and Neoadjuvant Therapy, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Enrolling by invitation at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
190th of 235
32 · median 90
Started
2025
with 27 others
Phase 2/3
6 of 252
4 open now
Primary completion
2027-06
later than 91 of 152 live
Registered
199th of 252
by date
Lead sponsor
4 of 252
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 190th largest by planned enrollment of the 235 interventional ones that give a count, is one of 28 that started in 2025, is one of 6 in phase 2/3, reaches primary completion later than 91 of the 152 other live ones, and was the 199th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a prospective, single-arm, multicenter study to observe and evaluate the efficacy and safety of paclitaxel polymeric micelles and carboplatin in combination with iparomilimab and tuvonralimab in neoadjuvant therapy for triple-negative breast cancer. The main endpoint of the study is pCR, 32 patients are scheduled to be enrolled.

03

Conditions studied

  • Triple-Negative Breast Cancer (TNBC)
  • Neoadjuvant Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Triple-negative breast cancer
  • The diameter of the primary tumor must be greater than 2cm, and the clinical stage should be II-III
  • There is sufficient primary organ function
  • The (PS) score is 0 or 1
  • Expected survival ≥ 6 months
  • The serum pregnancy test was negative. Use highly effective methods of during the study period and for 180 days after the last dose of the study drug, and do not breastfeed

Exclusion criteria

Exclusion Criteria:

  • Bilateral breast cancer
  • There is a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)
  • A history of invasive or breast cancer
  • Any diagnosed within 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or squamous cell carcinoma
  • There is an immune deficiency disease
  • The presence of any disease that still requires treatment or a history of prior autoimmune disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Chemotherapy combined with immunotherapy

    paclitaxel polymeric micelles 230-300mg/m2, d1 carboplatin AUC=5, d1 iparomilimab and tuvonralimab 5mg/kg, d1 Every 3 weeks (Q3W) is a cycle, a total of 6 cycles.

    Drug: paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab

Interventions

  • Drugpaclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab

    paclitaxel polymeric micelles 230-300mg/m2, d1 carboplatin AUC=5, d1 iparomilimab and tuvonralimab 5mg/kg, d1 Every 3 weeks (Q3W) is a cycle, a total of 6 cycles.

06

What researchers measure

Primary outcomes

  1. Primary endpoint

    Pathological complete response (pCR) rates in patients with triple-negative breast cancer

    Time frame: After surgery(within 1 month)

Secondary outcomes

  1. Objective response rate (ORR)

    Time frame: During neoadjuvant therapy before surgery(within 6 months)

  2. The rate of event-free Survival (EFS)

    Time frame: 2-year

  3. The incidence of treatment-related adverse event

    Time frame: 2-year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2025
First posted
Apr 4, 2025
StartActual
Jul 21, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Oct 1, 2028
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06910072
Responsible party
PENG YUAN (Professor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Apr 4, 2025
Start date
Jul 21, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Aug 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion